<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318706</url>
  </required_header>
  <id_info>
    <org_study_id>DS5565-A-J303</org_study_id>
    <nct_id>NCT02318706</nct_id>
  </id_info>
  <brief_title>DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain</brief_title>
  <official_title>An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles Malaysia Sdn. Bhd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the efficacy and safety of DS-5565 in subjects with Diabetic Peripheral&#xD;
      Neuropathic Pain (DPNP) in comparison to placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Double Blind Phase] The primary objective is to compare change in the Average Daily Pain&#xD;
      Score(ADPS) from baseline to Week 14 in Asian subjects with DPNP receiving DS-5565 versus&#xD;
      placebo.&#xD;
&#xD;
      [Open Extension Phase] The objective is to assess the long-term safety and efficacy of&#xD;
      DS-5565 in subjects with DPNP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 29, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</measure>
    <time_frame>Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])</time_frame>
    <description>Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary).&#xD;
In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</measure>
    <time_frame>From baseline (Week 14) to Week 66</time_frame>
    <description>Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome.&#xD;
In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">854</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group (14 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-5565 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-5565 20 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-5565 30 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-5565</intervention_name>
    <arm_group_label>DS-5565 15mg</arm_group_label>
    <arm_group_label>DS-5565 20 mg group</arm_group_label>
    <arm_group_label>DS-5565 30 mg group</arm_group_label>
    <other_name>mirogabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus at screening&#xD;
&#xD;
          -  Painful distal symmetric polyneuropathy&#xD;
&#xD;
          -  At screening, a pain scale of â‰¥ 40 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HbA1c (National Glycohemoglobin Standardization Program) &gt; 10.0%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saiki Central Hospital</name>
      <address>
        <city>Oita</city>
        <zip>876-0851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Peripheral Neuropathic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02318706/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 854 participants who met all inclusion and no exclusion criteria were enrolled; 834 were randomized to treatment in the double-blind phase. Twenty participants were excluded by the sponsor due to a serious Good Clinical Practice violation (inform consent form-related). A total of 214 participants enrolled in the open-label extension.</recruitment_details>
      <pre_assignment_details>Participants were randomized to DS-5565 (15, 20, or 30 mg) or placebo in the double-blind (DB) phase and open-label DS-5565 in the long-term (LT) phase. Patients who complete the DB phase may not enroll in the LT phase. DB phase determine significant difference vs placebo (~750 target cases). LT phase confirm long-term safety (~180 target cases).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants who received an oral dose of placebo twice daily (BID) for 14 weeks.</description>
        </group>
        <group group_id="P2">
          <title>DS-5565 15mg QD</title>
          <description>Participants who received an oral dose of DS-5565 15 mg every day (QD).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 5 mg (5 mg QD) during the first week and followed by 10 mg (10 mg QD) during the second week.&#xD;
During the fixed-dose period, a daily dose of 15 mg (15 mg QD) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>DS-5565 20 mg (10 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 20 mg (10 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for 1 week.&#xD;
During the fixed-dose period, a daily dose of 20 mg (10 mg BID) was administered orally for 13 weeks.</description>
        </group>
        <group group_id="P4">
          <title>DS-5565 30 mg (15 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 30 mg (15 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for the first week followed by 20 mg (10 mg BID) during the second week.&#xD;
During the fixed-dose period, a daily dose of 30 mg (15 mg BID) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>DS-5565 Open-label Extension</title>
          <description>Participants who received an oral dose of DS-5565 5 mg BID for the first 2 weeks and 10 mg BID for the second 2 weeks (i.e., Week 3 and 4). At Week 5, the dosage was escalated to 15 mg BID if there were no concerns in safety. For the subsequent visits, the dosage may have changed to either 10 mg BID or 15 mg BID depending on safety findings.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="334"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="166"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="142"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="214">A portion of participants who completed the double-blind phase enrolled in the open-label extension.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants who received an oral dose of placebo twice daily (BID) for 14 weeks.</description>
        </group>
        <group group_id="B2">
          <title>DS-5565 15mg QD</title>
          <description>Participants who received an oral dose of DS-5565 15 mg QD.&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 5 mg (5 mg QD) during the first week and followed by 10 mg (10 mg QD) during the second week.&#xD;
During the fixed-dose period, a daily dose of 15 mg (15 mg QD) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>DS-5565 20 mg (10 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 20 mg (10 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for 1 week.&#xD;
During the fixed-dose period, a daily dose of 20 mg (10 mg BID) was administered orally for 13 weeks.</description>
        </group>
        <group group_id="B4">
          <title>DS-5565 30 mg (15 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 30 mg (15 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for the first week followed by 20 mg (10 mg BID) during the second week.&#xD;
During the fixed-dose period, a daily dose of 30 mg (15 mg BID) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="166"/>
            <count group_id="B5" value="834"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="497"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="10.5"/>
                    <measurement group_id="B2" value="61.9" spread="8.4"/>
                    <measurement group_id="B3" value="61.2" spread="10.1"/>
                    <measurement group_id="B4" value="61.8" spread="9.4"/>
                    <measurement group_id="B5" value="61.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="166"/>
                    <measurement group_id="B5" value="834"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="166"/>
                    <measurement group_id="B5" value="834"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</title>
        <description>Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary).&#xD;
In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain.</description>
        <time_frame>Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])</time_frame>
        <population>ADPS was assessed in the Modified-Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received an oral dose of placebo twice daily (BID) for 14 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DS-5565 15mg QD</title>
            <description>Participants who received an oral dose of DS-5565 15 mg every day (QD).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 5 mg (5 mg QD) during the first week and followed by 10 mg (10 mg QD) during the second week.&#xD;
During the fixed-dose period, a daily dose of 15 mg (15 mg QD) was administered orally for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DS-5565 20 mg (10 mg BID)</title>
            <description>Participants who received an oral dose of DS-5565 20 mg (10 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for 1 week.&#xD;
During the fixed-dose period, a daily dose of 20 mg (10 mg BID) was administered orally for 13 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DS-5565 30 mg (15 mg BID)</title>
            <description>Participants who received an oral dose of DS-5565 30 mg (15 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for the first week followed by 20 mg (10 mg BID) during the second week.&#xD;
During the fixed-dose period, a daily dose of 30 mg (15 mg BID) was administered orally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</title>
          <description>Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary).&#xD;
In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain.</description>
          <population>ADPS was assessed in the Modified-Intent-to-Treat Analysis Set.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.79"/>
                    <measurement group_id="O2" value="-0.39" spread="0.67"/>
                    <measurement group_id="O3" value="-0.40" spread="0.85"/>
                    <measurement group_id="O4" value="-0.60" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.96"/>
                    <measurement group_id="O2" value="-0.60" spread="0.90"/>
                    <measurement group_id="O3" value="-0.72" spread="1.12"/>
                    <measurement group_id="O4" value="-1.00" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="1.08"/>
                    <measurement group_id="O2" value="-0.78" spread="1.02"/>
                    <measurement group_id="O3" value="-0.84" spread="1.22"/>
                    <measurement group_id="O4" value="-1.33" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="1.12"/>
                    <measurement group_id="O2" value="-0.87" spread="1.13"/>
                    <measurement group_id="O3" value="-0.94" spread="1.38"/>
                    <measurement group_id="O4" value="-1.43" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="1.17"/>
                    <measurement group_id="O2" value="-0.97" spread="1.20"/>
                    <measurement group_id="O3" value="-1.06" spread="1.50"/>
                    <measurement group_id="O4" value="-1.48" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="1.25"/>
                    <measurement group_id="O2" value="-1.01" spread="1.32"/>
                    <measurement group_id="O3" value="-1.13" spread="1.52"/>
                    <measurement group_id="O4" value="-1.58" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="1.31"/>
                    <measurement group_id="O2" value="-1.06" spread="1.40"/>
                    <measurement group_id="O3" value="-1.13" spread="1.59"/>
                    <measurement group_id="O4" value="-1.57" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="1.39"/>
                    <measurement group_id="O2" value="-1.07" spread="1.49"/>
                    <measurement group_id="O3" value="-1.26" spread="1.59"/>
                    <measurement group_id="O4" value="-1.53" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.42"/>
                    <measurement group_id="O2" value="-1.13" spread="1.49"/>
                    <measurement group_id="O3" value="-1.27" spread="1.56"/>
                    <measurement group_id="O4" value="-1.63" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.44"/>
                    <measurement group_id="O2" value="-1.19" spread="1.56"/>
                    <measurement group_id="O3" value="-1.33" spread="1.65"/>
                    <measurement group_id="O4" value="-1.67" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="1.46"/>
                    <measurement group_id="O2" value="-1.23" spread="1.57"/>
                    <measurement group_id="O3" value="-1.36" spread="1.64"/>
                    <measurement group_id="O4" value="-1.69" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.50"/>
                    <measurement group_id="O2" value="-1.24" spread="1.60"/>
                    <measurement group_id="O3" value="-1.36" spread="1.67"/>
                    <measurement group_id="O4" value="-1.82" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.55"/>
                    <measurement group_id="O2" value="-1.27" spread="1.63"/>
                    <measurement group_id="O3" value="-1.43" spread="1.72"/>
                    <measurement group_id="O4" value="-1.85" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.60"/>
                    <measurement group_id="O2" value="-1.34" spread="1.74"/>
                    <measurement group_id="O3" value="-1.47" spread="1.69"/>
                    <measurement group_id="O4" value="-1.88" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 14 change from baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>DS-5565 20 mg and 30 mg are tested against placebo at significance level of 0.025, respectively. If both arms are statistically significant, DS-5565 15 mg arm will be tested at level of 0.05. If neither of the arms is statistically significant, DS-5565 15 mg arm is no longer tested. If either DS-5565 20 mg or DS-5565 30 mg is statistically significant, DS-5565 15 mg arm is tested at level of 0.025.</non_inferiority_desc>
            <p_value>0.8773</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 14 change from baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>DS-5565 20 mg and 30 mg are tested against placebo at significance level of 0.025, respectively. If both arms are statistically significant, DS-5565 15 mg arm will be tested at level of 0.05. If neither of the arms is statistically significant, DS-5565 15 mg arm is no longer tested. If either DS-5565 20 mg or DS-5565 30 mg is statistically significant, DS-5565 15 mg arm is tested at level of 0.025.</non_inferiority_desc>
            <p_value>0.3494</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 14 change from baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>DS-5565 20 mg and 30 mg are tested against placebo at significance level of 0.025, respectively. If both arms are statistically significant, DS-5565 15 mg arm will be tested at level of 0.05. If neither of the arms is statistically significant, DS-5565 15 mg arm is no longer tested. If either DS-5565 20 mg or DS-5565 30 mg is statistically significant, DS-5565 15 mg arm is tested at level of 0.025.</non_inferiority_desc>
            <p_value>0.0027</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</title>
        <description>Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome.&#xD;
In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity.</description>
        <time_frame>From baseline (Week 14) to Week 66</time_frame>
        <population>Visual analog scale was assessed in all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-5565 Open-label Extension</title>
            <description>Participants who received an oral dose of DS-5565 5 mg BID for the first 2 weeks and 10 mg BID for the second 2 weeks (i.e., Week 3 and 4). At Week 5, the dosage was escalated to 15 mg BID if there were no concerns in safety. For the subsequent visits, the dosage may have changed to either 10 mg BID or 15 mg BID depending on safety findings.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain</title>
          <description>Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome.&#xD;
In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity.</description>
          <population>Visual analog scale was assessed in all enrolled participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="9.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="11.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" spread="12.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="11.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.20" spread="12.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="13.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.30" spread="15.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.00" spread="14.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.10" spread="15.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="15.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.20" spread="14.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.80" spread="14.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" spread="15.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.80" spread="13.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected after the participant signed the informed consent up to 7 days after the last dose of the study drug (the post-treatment follow-up visit [Visit 11]), up to 2 years 6 months.</time_frame>
      <desc>A total of 824 participants were included in the Safety Analysis Set. An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory value or abnormal vital sign), symptom, or disease that developed, regardless of relationship to the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants who received an oral dose of placebo twice daily (BID) for 14 weeks.</description>
        </group>
        <group group_id="E2">
          <title>DS-5565 15mg QD</title>
          <description>Participants who received an oral dose of DS-5565 15 mg every day (QD).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 5 mg (5 mg QD) during the first week and followed by 10 mg (10 mg QD) during the second week.&#xD;
During the fixed-dose period, a daily dose of 15 mg (15 mg QD) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>DS-5565 20 mg (10 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 20 mg (10 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for 1 week.&#xD;
During the fixed-dose period, a daily dose of 20 mg (10 mg BID) was administered orally for 13 weeks.</description>
        </group>
        <group group_id="E4">
          <title>DS-5565 30 mg (15 mg BID)</title>
          <description>Participants who received an oral dose of DS-5565 30 mg (15 mg BID).&#xD;
During the titration period, DS-5565 was administered orally at a daily dose of 10 mg (5 mg BID) for the first week followed by 20 mg (10 mg BID) during the second week.&#xD;
During the fixed-dose period, a daily dose of 30 mg (15 mg BID) was administered orally for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>DS-5565 Open-label Extension</title>
          <description>Participants who received an oral dose of DS-5565 5 mg BID for the first 2 weeks and 10 mg BID for the second 2 weeks (i.e., Week 3 and 4). At Week 5, the dosage was escalated to 15 mg BID if there were no concerns in safety. For the subsequent visits, the dosage may have changed to either 10 mg BID or 15 mg BID depending on safety findings.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="141" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>1-908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

